122 related articles for article (PubMed ID: 9075480)
1. Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals.
Klein MR; Veenstra J; Holwerda AM; Roos MT; Gow I; Patou G; Coutinho RA; De Wolf F; Miedema F
AIDS Res Hum Retroviruses; 1997 Mar; 13(5):393-9. PubMed ID: 9075480
[TBL] [Abstract][Full Text] [Related]
2. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers.
Weber J; Cheinsong-Popov R; Callow D; Adams S; Patou G; Hodgkin K; Martin S; Gotch F; Kingsman A
Vaccine; 1995 Jun; 13(9):831-4. PubMed ID: 7483805
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.
Lindenburg CE; Stolte I; Langendam MW; Miedema F; Williams IG; Colebunders R; Weber JN; Fisher M; Coutinho RA
Vaccine; 2002 May; 20(17-18):2343-7. PubMed ID: 12009290
[TBL] [Abstract][Full Text] [Related]
5. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons.
Veenstra J; Williams IG; Colebunders R; Dorrell L; Tchamouroff SE; Patou G; Lange JM; Weller IV; Goeman J; Uthayakumar S; Gow IR; Weber JN; Coutinho RA
J Infect Dis; 1996 Oct; 174(4):862-6. PubMed ID: 8843231
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals.
Benson EM; Clarkson J; Law M; Marshall P; Kelleher AD; Smith DE; Patou G; Stewart GJ; Cooper DA; French RA
AIDS Res Hum Retroviruses; 1999 Jan; 15(2):105-13. PubMed ID: 10029243
[TBL] [Abstract][Full Text] [Related]
8. Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study.
O'Toole CM; Lowdell MW; Chargelegue D; Colvin BT
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1361-8. PubMed ID: 1281655
[TBL] [Abstract][Full Text] [Related]
9. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities.
Koup RA; Pikora CA; Luzuriaga K; Brettler DB; Day ES; Mazzara GP; Sullivan JL
J Exp Med; 1991 Dec; 174(6):1593-600. PubMed ID: 1744586
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals.
Seth A; Yasutomi Y; Jacoby H; Callery JC; Kaminsky SM; Koff WC; Nixon DF; Letvin NL
AIDS Res Hum Retroviruses; 2000 Mar; 16(4):337-43. PubMed ID: 10716371
[TBL] [Abstract][Full Text] [Related]
11. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
12. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
[TBL] [Abstract][Full Text] [Related]
14. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.
Kalams SA; Buchbinder SP; Rosenberg ES; Billingsley JM; Colbert DS; Jones NG; Shea AK; Trocha AK; Walker BD
J Virol; 1999 Aug; 73(8):6715-20. PubMed ID: 10400769
[TBL] [Abstract][Full Text] [Related]
15. HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1.
Mills KH; Kitchin PA; Mahon BP; Barnard AL; Adams SE; Kingsman SM; Kingsman AJ
J Immunol; 1990 Mar; 144(5):1677-83. PubMed ID: 1689753
[TBL] [Abstract][Full Text] [Related]
16. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
[TBL] [Abstract][Full Text] [Related]
17. Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection.
Feeney ME; Draenert R; Roosevelt KA; Pelton SI; McIntosh K; Burchett SK; Mao C; Walker BD; Goulder PJ
J Immunol; 2003 Dec; 171(12):6968-75. PubMed ID: 14662905
[TBL] [Abstract][Full Text] [Related]
18. Fine-specificity of cytotoxic T lymphocytes which recognize conserved epitopes of the Gag protein of human immunodeficiency virus type 1.
van Baalen CA; Klein MR; Huisman RC; Dings ME; Kerkhof Garde SR; Geretti AM; Gruters R; van Els CA; Miedema F; Osterhaus AD
J Gen Virol; 1996 Aug; 77 ( Pt 8)():1659-65. PubMed ID: 8760412
[TBL] [Abstract][Full Text] [Related]
19. Association between HIV Type 1-specific T cell responses and CD4+ T cell counts or CD4+:CD8+ T cell ratios in HIV Type 1 subtype B infection in China.
Wang S; Zhuang Y; Zhai S; Zhao S; Kang W; Li X; Yu XG; Walker BD; Altfeld MA; Sun Y
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):780-7. PubMed ID: 16910834
[TBL] [Abstract][Full Text] [Related]
20. Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.
Ratto-Kim S; Garner RP; Kim JH; Jagodzinski LL; Michael NL; Paris R; Redfield RR; Birx DL
J Infect Dis; 2004 Jun; 189(11):1988-95. PubMed ID: 15143464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
